Publication

Article

Oncology Treatment Pathways®

November 2022
Volume

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Download Issue PDF
Articles in this issue
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Related Videos
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Related Content
FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

FDA
December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

OncLive’s November Roundup of Key FDA Approvals in Oncology
December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024